SavedAdd your journal

Journals / Balkan Medical Journal / 2018 / Cilt: 35 - Sayı: 5

Early Retinal and Choroidal Coat Thickness Changes after Intravitreal Dexamethasone Implant Injection for Diabetic Macular Edema

Özkan SEVER
Fatih HOROZOĞLU
Pages
384–387
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Centralmacular thickness measurements decreased significantly in the firsthour (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Intravitreal steroid injection is one of the treatmentoptions for diabetic macular edema.
📊
Key Findings & Data:Improvementin macular thickness is a well-known effect of Dexamethasoneimplant however, subfoveal choroidal coat thickness changes requireinvestigation.Aims: To evaluate the early central macular thickness and subfovealchoroidal thickness alterations after single-dose dexamethasoneimplant injection in diabetic macular edema.Study Design: Cross-sectional study.Methods: We identified 29 patients with diabetic macular edema(29 eyes) who underwent optical coherence tomography andfundus fluorescein angiography.
💡
Conclusion & Impact:Centralmacular thickness measurements decreased significantly in the firsthour (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Intravitreal steroid injection is one of the treatmentoptions for diabetic macular edema. Dexamethasone implant isthe most novel form of intravitreal steroid therapy. Improvementin macular thickness is a well-known effect of Dexamethasoneimplant however, subfoveal choroidal coat thickness changes requireinvestigation.Aims: To evaluate the early central macular thickness and subfovealchoroidal thickness alterations after single-dose dexamethasoneimplant injection in diabetic macular edema.Study Design: Cross-sectional study.Methods: We identified 29 patients with diabetic macular edema(29 eyes) who underwent optical coherence tomography andfundus fluorescein angiography. All patients received a single-doseintravitreal Dexamethasone implant and were followed up for centralmacular thickness and subfoveal choroidal thickness alterations for 1hour, 1 week, 1 month, and 3 months post-injection.Results: The preoperative mean central macular thickness andsubfoveal choroidal thickness measurements were 592.3±122.3(412–879) μm and 264.8±53.7 (165–397) μm, respectively. Centralmacular thickness measurements decreased significantly in the firsthour (p

🔖

Cite This Article

SEVER, Ö., HOROZOĞLU, F. (2022). Early Retinal and Choroidal Coat Thickness Changes after Intravitreal Dexamethasone Implant Injection for Diabetic Macular Edema. Balkan Medical Journal, Cilt: 35 - Sayı: 5, 384–387. https://ajindex.com/articles/461076

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Boyer DS, Faber D, Gupta S, Tabandeh H, Li XY, Liu CC, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011;31:915-23.
  2. Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology 2014;121:2473-81.
  3. Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013;120:1843-51.
  4. Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128:289-96.
  5. Sonoda S, Sakamoto T, Yamashita T, Otsuka H, Shirasawa M, Kakiuchi N, et al. Effect of intravitreal triamcinolone acetonide or bevacizumab on choroidal thickness in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 2014;55:3979-85.
  6. Okamoto M, Matsuura T, Ogata N. Effects of panretinal photocoagulation on choroidal thickness and choroidal blood flow in patients with severe nonproliferative diabetic retinopathy. Retina 2016;36:805-11.
  7. Ozdogan Erkul S, Kapran Z, Uyar OM. Quantitative analysis of subfoveal choroidal thickness using enhanced depth imaging optical coherence tomography in normal eyes. Int Ophthalmol 2014;34:35-40.
  8. Kim JT, Lee DH, Joe SG, Kim JG, Yoon YH. Changes in choroidal thickness in relation to the severity of retinopathy and macular edema in type 2 diabetic patients. Invest Ophthalmol Vis Sci 2013;54:3378-84.
  9. Regatieri CV, Branchini L, Carmody J, Fujimoto JG, Duker JS. Choroidal thickness in patients with diabetic retinopathy analyzed by spectral-domain optical coherence tomography. Retina 2012;32:563-8.
  10. Rayess N, Rahimy E, Ying GS, Bagheri N, Ho AC, Regillo CD, et al. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema. Am J Ophthalmol 2015;159:85-91.
  11. Chung YR, Kim JW, Kim SW, Lee K. Choroidal thickness in patients with central serous chorioretinopathy: assessment of Haller and Sattler layers. Retina 2016;36:1652-7.
  12. Cheng H, Kaszubski PA, Hao H, Saade C, Cunningham C, Freund KB, et al. The Relationship between Reticular Macular Disease and Choroidal Thickness. Curr Eye